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Heparins are efficient inhibitors of hepcidin expression even in vivo, where they induce
an increase of systemic iron availability. Heparins seem to act by interfering with
BMP6 signaling pathways that control the expression of liver hepcidin, causing the
suppression of SMAD1/5/8 phosphorylation. The anti-hepcidin activity persists also
when the heparin anticoagulant property is abolished or reduced by chemical reactions
of oxidation/reduction (glycol-split, Gs-Heparins) or by high sulfation (SS-Heparins), but
the structural characteristics needed to optimize this inhibitory activity have not been
studied in detail. To this aim we analyzed three different heparins (Mucosal Heparin,
the Glycol split RO-82, the partially desulfated glycol-split RO-68 and the oversulfated
SSLMWH) and separated them in fractions of molecular weight in the range 4–16 kD.
Since the distribution of the negative charges in heparins contributes to the activity,
we produced 2-O- and 6-O-desulfated heparins. These derivatives were analyzed for
the capacity to inhibit hepcidin expression in hepatic HepG2 cells and in mice. The
two approaches produced consistent results and showed that the anti-hepcidin activity
strongly decreases with molecular weight below 7 kD, with high N-acetylation and after
2-O and 6-O desulfation. The high sulfation and high molecular weight properties for
efficient anti-hepcidin activity suggest that heparin is involved in multiple binding sites.
Keywords: iron metabolism, hepcidin, low molecular weight heparins, 2-O and 6-O sulfated heparins, BMP6,
anemia of chronic diseases
INTRODUCTION
Iron is essential and potentially toxic, thus its homeostasis needs to be tightly regulated. In
mammals the control of the systemic iron regulation relies mainly on hepcidin, which controls
iron availability by suppressing ferroportin, the iron exporter (Ganz and Nemeth, 2012). Hepcidin
expression, in turn, is regulated by systemic and hepatic iron stores, by erythropoietic activity,
ER stress, hypoxia and inﬂammatory conditions (Hentze et al., 2010), with mechanisms that
involve primarily the BMP/SMAD signaling pathway (Babitt et al., 2007). Among the various
BMP members, BMP6 is the one dedicated to hepcidin expression, it binds to BMP receptors
of type I (ALK2 and 3) and type II (AcvR2 and BMPR2) causing the phosphorylation of
SMAD1/5/8 which assemble with SMAD4 and transfer into the nucleus to activate hepcidin
Abbreviations: BMP, bone morphogenetic protein, SMAD, small mother against decapentaplegic, STAT, signal transducer
and activator of transcription; IL-6, interleukin -6.
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promoter (Core et al., 2014). The mechanism includes other
actors, like hemojuvelin (HJV), a GPI-anchor protein, that acts
as BMP co-receptor (Babitt et al., 2006) and the serine protease
TMPRSS6 that controls HJV activity. The inﬂammatory response
induces hepcidin expression via the IL6-dependent activation of
JAK/STAT3 signaling (Verga Falzacappa et al., 2007). Abnormal
regulation of hepcidin expression occurs in various pathologies:
when too low it leads to iron excess as in hemochromatosis
(Zhao et al., 2013), when hepcidin is too high it leads to
iron restriction, as in Iron Refractory Iron Deﬁciency Anemia
(IRIDA) and in the Anemia of Chronic Disease (ACD) (Poli
et al., 2014c). ACD is a common form of anemia associated
with degenerative diseases including cancer, chronic kidney
disease and rheumatoid arthritis. The pharmacological controls
of hepcidin should improve the treatment of various disorders
of iron metabolism, including ACD. Diﬀerent approaches are
in study for treatments to control hepcidin (Ganz and Nemeth,
2011; Fung and Nemeth, 2013; Poli et al., 2014c) and among
them we found that heparins strongly repress liver hepcidin
expression in vitro and in vivo (Poli et al., 2011, 2014a)
by interfering with BMP6/SMAD1/5/8 phosphorylation and
signaling (Poli et al., 2014a). The ﬁnding that this occurs also with
heparins without anticoagulant activity strongly facilitated their
use in vivo. For example, the glycol-split heparins (gs-Heparins)
(Poli et al., 2014a) and the oversulfated heparins (SS-heparins)
suppress hepcidin and increase iron availability in mice (Poli
et al., 2014a,b) with no adverse eﬀect. However, the heparin
preparations normally used are heterogeneous and composed by
molecules with diﬀerent molecular weight and degree/topology
of sulfation and their use do not provide precise indications on
the chemical properties for optimal anti-hepcidin activity. To
this aim we prepared and analyzed more homogenous heparin
preparations with deﬁned molecular weight and that have been
treated to remove sulfate groups from oxygen 2 of iduronic
acid (2-O) and from oxygen 6 of glucosamine residues (6-O).
The results show that the anti-hepcidin activity is associated
with molecular weight above 7 kD and with the 2-O and 6-O
sulfation.
MATERIALS AND METHODS
Heparin Derivatives
Heparin is an API porcine mucosal Heparin (PMH) (Bioiberica
lot F415-10/0001). The chemically modiﬁed non-anticoagulant
heparins RO-82 and RO-68 obtained by oxidation and reduction,
and the 2-O and 6-O desulfated heparin samples were
prepared as described in (Naggi et al., 2005). They diﬀer
in the degree of sulfation and the number of glycol-split
residues for chain. Fractions with diﬀerent molecular weight of
samples MH, RO-82, RO-68, SSLMWH-19 were obtained by
gel ﬁltration through Ultrogel ACA54 (Sigma Aldrich) column
(1.5 cm × 84 cm) equilibrated in 0.25 M NH4Cl. All samples
were recovered after desalting on TSK HW 40S column (Tosoh
Bioscience, Belgium) then were freeze-dried and characterized
by NMR spectroscopy, (Guerrini et al., 2005) by conductimetric
determination of SO3/COO- ratio (Casu and Gennaro, 1975),
and by determination of average molecular weight (Bertini
et al., 2005). Characteristics of the samples are reported in
Table 1.
Cell Culture
The human hepatoma cell lines, HepG2 (from IZSLER, Brescia,
Italy) were cultured in minimum essential medium (MEM, Gibco
from Life technologies), 10% endotoxin-free fetal bovine serum
(Sigma–Aldrich), 0.04 mg/mL gentamicin (Gibco), 2 mM L-
glutamine (Gibco), and 1 mM sodium pyruvate (Carlo Erba) and
maintained at 37◦C in 5% CO2.
Mice
The study was approved by the Institutional Animal Care and
Use Committee of the University of Brescia, Italy. C57BL/J6 mice
(Harlan Laboratories) were kept on a standard diet until 8 or
9 weeks. Four mice per experimental group were used for the
treatment mentioned below, treated subcutaneously (SC) with
saline or diﬀerent heparins.
Treatments with Heparins
In Vitro
Heparins were dissolved in sterile saline buﬀer at a concentration
of 10 µg/µl for in vitro studies and stored at 4◦C. Just before
using, serial dilutions of them were prepared (33-11-3.6-1.2-0.4-
0.12 µg/ml) in culture medium and they were added to the cells
in the presence or the absence of BMP6 (10 ng/ml) (R&D) for 6 h.
After the treatment the cells were collected and RNA extracted as
reported below.
In Vivo
Heparins were dissolved in sterile saline buﬀer to the proper
concentration to inject SC in the mice of the selected amount in a
volume of 100–150µl/mouse. The control group was treated with
the same volume of sterile saline buﬀer. After 6 h the mice were
euthanized, the liver RNA extracted and analyzed for mRNA of
hepcidin, Id1 and Hprt1.
RNA extraction and Quantitative
qRT-PCR
After the treatments, total cell RNA was recovered with TRI
Reagent (Sigma–Aldrich), according to the manufacturer’s
TABLE 1 | Average molecular weight (Mw) rounded to 100s D of the
fractions obtained from four different heparin types: the unmodified
Mucosal Heparin (MH), the 30% glycol-split RO-82, the partially desulfated
42% glycol-split RO-68 and the ovesulfated SSLMWH-19.
Mw (kD)
Sample MH RO-82 RO-68 SSLMWH-19
Parent 17.20 16.00 16.40 8.80
Fraction 1 21.60 12.00 7.80 12.90
Fraction 2 14.40 9.20 6.20 10.30
Fraction 3 10.00 7.80 3.90 6.90
Fraction 4 – 6.80 – 4.00
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FIGURE 1 | Analysis of different heparin type fractions with different molecular weight. (A) The fractions of the four different heparins, listed in Table 1 were
added to HepG2 cells at the concentration of 3.6 µg/ml for 6 h in presence of 10 ng/mL BMP6 and then the level of hepcidin mRNAs evaluated by qRT-PCR. The
residual levels of hepcidin mRNA are plotted vs. the molecular weight of the fractions. (B) Dose-response curves of the two unfractionated RO heparins (RO-82 and
RO-68), of their lightest fractions of 6.8 and 3.9 kD and of their highest fractions of 12 and 7.8 kD. HepG2 cells were treated with 0.4-1.2-3.6-11-33 µg/ml of
different heparins for 6 h, in the presence of 10 ng/ml BMP6. The values were normalized for Hprt1 and the means were reported as fold increase of BMP6
stimulated cells, considered as control (value 1 in A,B). Three independent experiments for (A,B) graphs were performed and the induction of hepcidin expression in
presence of BMP6 was reported as fold increase vs. untreated but stimulated cells. (C) The indicated compounds were injected subcutaneously in the mice at the
concentrations of 40 mg/Kg for RO-82, RO-68; RO-82 6.8 kD, RO-68 3.9 kD and of 20 mg/ml for SSH-19 (SSLMWH-19) and SSH-19 4 kD. The mice were
sacrificed after 6 h and the liver hepcidin mRNA quantified by qRT-PCR. The values were normalized for Hprt1 and reported in a box plot as a percentage of saline
treated mice (CTRL).∗ and ∗∗ is a P-value <0.005 or 0.001 respectively.
instruction. Reverse transcription was performed using 1 µg
RNA, oligo dT, and Improm Reverse Transcriptase (Promega)
in 20 µL. Samples (1 µl) were used for quantitative reverse
transcription polymerase chain reaction (qRT-PCR) assay,
using iTAq Universal SYBR Green (Bio-Rad), according to
the manufacturer’s instructions. Primers used for human cell
lines were HsHamp forward, 5′-CCA-GCTGGA-TGC-CCA-
TGT-T-3′, and reverse, 5′-GCC-GCA-GCA-GAA-AATGCA-3′;
HsHprt1 forward, 5′-TGC-TTT-CCT-TGG-TCA-GGC-AG-3′,
and reverse, 5′-AAG-CTT-GCG-ACC-TTG-ACC-AT-3′. The
same procedure was used for mouse liver and the primers for
quantitative real-time RT-PCR assay were: MmHamp1 forward,
5′-AAG-CAG-GGC-AGA-CAT-TGC-GAT-3′, and reverse, 5′-
CAG-GAT-GTG-GCT-CTA-GGC-TAT-GT-3′; MmHprt1
forward, 5′-CTG-GTT-AAG-CAG-TAC-AGC-CCC-AA-3′, and
reverse, 5′-CAGGAG-GTC-CTT-TTC-ACC-AGC-3′; MmId1
forward, 5′-ACC-CTG-AACGGC-GAG-ATC-A-3′, and reverse,
5′-TCG-TCG-GCT-GGA-ACA-CAT-G-3′.
Statistical Analysis
Data are presented as mean ± standard error of mean (SD).
Data of in vitro experiments are expressed as percentage or fold
increase with respect to non-stimulated/non-treated cells. The
data of in vivo experiments are expressed as percentage with
respect to untreated animals and represented with box plots
(for a better visualization of mice distribution in each group).
Comparison of values between untreated and treated cells or mice
was performed by two-tailed Student t-test for unpaired data.
Diﬀerences were deﬁned as signiﬁcant for P < 0.05 or 0.001.
RESULTS
We previously found that unfractionated, glycol-split and
oversulfated heparins are eﬃcient suppressors of hepcidin. We
also observed that high N-acetylation reduced the anti-hepcidin
potency of these compounds, whereas oversulfation increased it
(Poli et al., 2014a). However, other heparin properties for optimal
anti-hepcidin activity remained to be characterized, in particular
the molecular weight and the sulfation at the crucial 2-O and 6-O
positions.
Heparin Molecular Weight
To analyze the role of molecular weight, previously characterized
heparins with high anti-hepcidin activity were fractionated by
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FIGURE 2 | Analysis of 2-O and 6-O desulfated mucosal heparins. The unfractionated and unmodified Mucosal Heparin (MH) and of the two desulfated
preparations (2-O and 6-O) were added to HepG2 at different concentrations (0.12-0.4-1.2-3.6-11 µg/ml) for 6 h without (A) or in presence (B) of BMP6 (10 ng/ml).
The level of hepcidin mRNA was evaluated by qRT-PCR after 6 h of treatment and normalized for Hprt1. Three independent experiments for (A,B) were performed
and the mean values expressed in logarithmic scale vs. untreated cells (value 1) were reported in the graphs. (C,D) The heparins (RO-82, 2-O and 6-O) were injected
subcutaneously in the mice at the concentration of 40 mg/Kg. The mice were sacrificed after 6 h and the liver hepcidin and Id1 mRNA quantified by qRT-PCR. The
values were normalized for Hprt1 and reported in a box plot as a percentage of saline treated mice (CRTL). Id1 was a control of the activation of the BMP/SMAD
pathway. ∗∗ is a P-value <0.001.
FIGURE 3 | Molecular model of an octasaccharide segment of heparin
(Mulloy et al., 1993). The structure shows a regular distribution of sulfated
groups on both sides of the molecule. Circles indicate the position of the
hydroxyl in position 3.
gel permeation chromatography. They include the unfractionated
porcine mucosal heparin (MH), the glycol-split RO-82, the
partially desulfated glycol-split RO-68 (Poli et al., 2014a) and
the oversulfated SSLMWH-19 (Poli et al., 2014b). The chemical
characteristics of the fractions are listed in Table 1. We collected
and analyzed the lighter fractions of RO heparins because we
wanted to deﬁne the minimum molecular weight with high anti-
hepcidin activity, while for the oversulfated heparins that have
a low mean molecular weight, we collected also the heavier
fractions. To test their anti-hepcidin activity 3.6 µg/ml of the
samples were added to HepG2 cells together with 10 ng/ml of
BMP6, and after 6 h the hepcidin mRNA level quantiﬁed by
qPCR. The residual level of hepcidin mRNA of the treated cells
was plotted vs the molecular weight of each heparin fraction
(Figure 1A). The potency of the four heparins decreased with
the molecular weight. The plots of MH, RO-82 and RO-68 were
similar and almost overlapping, with a strong decrease of potency
below 7–10 kD. The oversulfated SSLMWH-19 was more potent,
as reported before (Poli et al., 2014b) and it was inhibitory even
at lower molecular weight, with a threshold of about 4 kD. The
fractions of glycol-split heparins with lower molecular weight
(RO-82 6.8 kD and RO-68 3.9 kD) could increase their activity at
higher concentrations, thus we performed dose-response studies
of these fractions in presence of BMP6 (10 ng/ml) for 6 h. The
inhibition of hepcidin expression reached a plateau at 3.6 µg/ml
for all heparins, but it accounted to about 50% for the low
molecular weight fractions and for RO-68 7.8 kD versus a 90%
of the parent preparations and the RO-82 12 kD (Figure 1B).
Next, we tested the heparin fractions in vivo by injecting
them SC in mice and analyzing liver hepcidin mRNA after 6 h.
Under these conditions the parental RO-82 and RO-68 at the
dose of 40 mg/kg were fully inhibitory, as reported before (Poli
et al., 2014a), while at the same dose their low molecular weight
fractions of 3.9 and 6.8 kD showed no inhibition (Figure 1C). In
vivo the RO-68 7.8 kD showed a similar anti-hepcidin activity to
the RO-82 6.8 kD, whereas the RO-82 12 kD was as potent as the
parent preparations (not shown). Interestingly, the oversulfated
heparin (SSLMW-19) of 8.8 kD retained a strong activity even
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at the lower dose of 20 mg/kg causing about 90% suppression of
hepcidin and also the lighter fraction of 4 kD retained the capacity
to inhibit hepcidin (with a reduction of 50%). These results are in
agreement with our previous report of a higher potency of the
oversulfated heparins (Poli et al., 2014b).
Sulfation at 2-O and 6-O
Heparin binding activity is related not only to the density of
sulfated groups but also on their spatial distribution, in particular
their presence on the 2-O or the 6-O. Thus we tested the
potency of inhibiting hepcidin expression in HepG2 of the
heparins treated to remove sulfates from 2-O and from 6-O. The
dose-response plots in Figures 2A,B showed that the hepcidin
inhibitory activity of the two modiﬁed heparins is comparable
and much lower of that of the control heparin (MH), both when
the experiments were performed in the absence (Figure 2A)
or the presence of 10 ng/ml BMP6 (Figure 2B). Then, we
used these heparins at a dose of 40 mg/kg to treat the mice.
The unfractionated RO heparin fully suppressed liver hepcidin
mRNA after 6 h of treatment, while the 2-O and 6-O desulfated
heparins showed no inhibitory activity at the same conditions
(Figure 2C). The analysis of Id1 mRNA, considered a reliable
index of activation of the BMP/SMAD pathway, conﬁrmed the
lack of activity of the two desulfated heparins (Figure 2D).
DISCUSSION
Heparins are promising anti-hepcidin agents that may ﬁnd an
application in the treatment of iron deﬁciencies linked to excess
of hepcidin (Poli et al., 2014c). They are active also after the
abolition/reduction of the anticoagulant property, typical of
these compounds, facilitating their use in vivo and in chronic
treatments. For this reason, an optimization of the molecular
structure that inhibits hepcidin expression in the cells and
in mice is important to improve the potency of this drug
and also to obtain information on the mechanism of hepcidin
inhibition. We have previously shown also that the oversulfation
improves anti-hepcidin activity (Poli et al., 2014b). Moreover
we have shown that the increase of N-acetylation decreases
heparin activity, in line with the observation that N-acetylation
reduces the degree of sulfation of the molecule (Poli et al.,
2014a). In this work we explored the eﬀect of molecular weight
and of 2-O and 6-O sulfation on the anti-hepcidin activity,
properties that were not analyzed in detail before. We separated
by gel ﬁltration various fractions of 4 diﬀerent heparin types
(one mucosal unmodiﬁed, two glycol split and one oversulfated
heparins) with molecular weights ranging from about 20 kD
to about 4 kD. We found that the anti-hepcidin activity of the
unmodiﬁed or glycol-split heparins strongly decreased below
about 10 kD, which corresponds to a 25-saccharide, while
that of the oversulfated heparin dropped at molecular weight
below 7 kD, which corresponds to ∼17-saccharide. This suggests
that for maximal activity, the heparin should expose various
highly sulfated binding sites, possibly acting by binding diﬀerent
molecules or diﬀerent sites of the same molecules. In fact
oversulfated heparins, even with molecular weight as low as 4 kD
(∼10 saccharide) are able to reduce hepcidin in vitro and in vivo.
The other major observation of this work is that the removal
of the sulfates from the 2-O and 6-O positions have a negative
dramatic eﬀect on heparin activity. This indicates that both the
residues are essential for the interaction and may suggest that
the sequences needed for the interaction request a cluster of
sulfate groups on the same size of the chain, and this, in the
oversulfated can be reinforced by the presence of sulfate also
in position 3 of glucosamine (see Figure 3).We also found an
interesting parallelism between the heparin capacity to inhibit
hepcidin mRNA expression in hepatic cells, and that to inhibit
hepcidin mRNA when injected SC in the mice. Further studies
are in progress to verify whether the oversulfated heparins act
in alternative way by interacting with BMP receptors, as it was
shown to occur in C2C12 and PC12 cells (Kuo et al., 2010).
CONCLUSION
For optimal anti-hepcidin activity, both in vitro and in vivo, the
heparins must have a high level of sulfation, which includes the
sulfation of 2-O, 6-O and also N-Acetylation degree of about 14–
14.6%, and a molecular weight above 6–10 kD, depending upon
the level of sulfation.
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